Análisis de 5 Fuerzas de Myriad Genetics, Inc. (MYGN) [Actualizado en enero de 2025]

En el panorama de diagnóstico genético en rápida evolución, Myriad Genetics, Inc. se encuentra en la encrucijada de innovación, competencia y desafíos estratégicos. A medida que la compañía navega por el complejo terreno de las pruebas moleculares, una inmersión profunda en las cinco fuerzas de Michael Porter revela una imagen matizada de la dinámica del mercado que dará forma a su trayectoria en 2024. Desde la intrincada danza de las relaciones de proveedores hasta las crecientes presiones de las expectativas del cliente y la tecnología de la tecnología. Irrupción, este análisis descubre las fuerzas críticas que determinarán la posicionamiento competitivo de la genética de innumeridad en el ecosistema de medicina de precisión.

Myriad Genetics, Inc. (Mygn) - Las cinco fuerzas de Porter: poder de negociación de los proveedores

Número limitado de equipos especializados de prueba genética y fabricantes de reactivos

A partir de 2024, el mercado global de equipos de prueba genética se concentra con aproximadamente 5-7 fabricantes principales. Thermo Fisher Scientific, Illumina y Roche Diagnostics controlan aproximadamente el 62.4% de la cuota de mercado para los equipos de prueba genética.

Fabricante	Cuota de mercado (%)	Ingresos anuales (USD)
Ilumina	35.2%	$ 4.2 mil millones
Thermo Fisher Scientific	15.7%	$ 44.9 mil millones
Roche Diagnostics	11.5%	$ 15.1 mil millones

Alta dependencia de biotecnología específicas y compañías de suministro médico

Myriad Genetics se basa en un número limitado de proveedores críticos para componentes especializados:

• Reactivos de secuenciación genómica
• Equipo de laboratorio de alta precisión
• Consumibles de pruebas genéticas especializadas

Costos significativos de investigación y desarrollo para tecnologías de prueba avanzadas

Las inversiones en I + D en tecnología de pruebas genéticas son sustanciales:

Compañía	Gastos anuales de I + D (USD)	I + D como % de ingresos
Innumerable genética	$ 98.4 millones	22.3%
Ilumina	$ 792 millones	25.6%

Posibles restricciones de la cadena de suministro en el diagnóstico médico de precisión

Los desafíos de la cadena de suministro en 2024 incluyen:

• Escasez de semiconductores globales que afectan el equipo de precisión
• Fabricantes limitados de reactivos de prueba genética de alto grado
• Regulaciones complejas de importación/exportación para tecnologías médicas especializadas

La evaluación del riesgo de interrupción de la cadena de suministro muestra un impacto potencial del 17.5% en la adquisición de tecnología de pruebas genéticas.

Myriad Genetics, Inc. (Mygn) - Las cinco fuerzas de Porter: poder de negociación de los clientes

Proveedores de atención médica y compañías de seguros de poder de negociación

En 2023, Myriad Genetics enfrentó importantes desafíos de negociación con las partes interesadas clave:

Tenedor de apuestas	Impacto de la negociación	Apalancamiento de precios
Principales proveedores de seguros	Tasa de negociación de cobertura del 80%	$ 350- $ 750 por prueba genética
Grandes redes de atención médica	65% de solicitudes de descuento basadas en volumen	12-18% de potencial de reducción de precios

Demanda de pacientes de pruebas genéticas personalizadas

La dinámica del mercado revela preferencias críticas del paciente:

• Tamaño del mercado de pruebas genéticas: $ 21.3 mil millones en 2023
• Tasa de crecimiento anual: 11.5% de 2024-2030
• Demanda de pruebas personalizadas: 67% de aumento año tras año

Complejidad del paisaje de reembolso

Los desafíos de reembolso incluyen:

Categoría de reembolso	Tasa de aprobación	Reembolso promedio
Seguro médico del estado	73%	$ 425 por prueba
Seguro privado	62%	$ 510 por prueba

Sensibilidad al precio en segmentos de pruebas genéticas

Métricas de sensibilidad de precios:

• PRUEBA ENCOLOGÍA Elasticidad del precio: -1.2
• Costo promedio de detección de cáncer hereditario: $ 3,800
• Rango de tolerancia al precio del consumidor: $ 250- $ 1,500

Myriad Genetics, Inc. (Mygn) - Las cinco fuerzas de Porter: rivalidad competitiva

Mercado de diagnóstico molecular panorama competitivo

A partir de 2024, el mercado de diagnóstico molecular demuestra una intensidad competitiva significativa con las siguientes características clave:

Competidor	Cuota de mercado	Ingresos anuales
Ilumina	42.3%	$ 4.2 mil millones
Invitae	15.7%	$ 517.4 millones
Innumerable genética	8.9%	$ 331.2 millones

Dinámica competitiva

Los factores de rivalidad competitivos incluyen:

• Número de competidores directos: 7 jugadores importantes
• Ratio de concentración de mercado: fragmentación moderada
• Aplicaciones de patentes de prueba genética en 2023: 124 Total en toda la industria

Métricas de innovación tecnológica

Categoría de innovación	Inversión	Gastos de I + D
Tecnologías de secuenciación genética	$ 276 millones	14.3% de los ingresos
Plataformas de medicina de precisión	$ 193 millones	9.7% de los ingresos

Paisaje legal y de patentes

• Disputas de patentes activas en 2023: 3 desafíos legales principales
• Costos de litigio de patentes: $ 4.2 millones
• Conflictos continuos de propiedad intelectual: principalmente en el dominio de pruebas de cáncer hereditario

Myriad Genetics, Inc. (Mygn) - Las cinco fuerzas de Porter: amenaza de sustitutos

Tecnologías emergentes de prueba genética alternativa

A partir de 2024, el mercado de pruebas genéticas muestra una diversificación tecnológica significativa:

Tecnología	Cuota de mercado (%)	Tasa de crecimiento anual
Secuenciación de próxima generación	42.3%	14.6%
Tecnología de microarrays	23.7%	8.2%
Prueba basada en PCR	18.5%	6.9%

Plataformas de prueba genética directa al consumidor

Panorama del mercado de plataformas de pruebas genéticas del consumidor:

• 23andMe: 6.5 millones de clientes
• Ancestry.com: 18 millones de clientes
• MyHeritage: 4.3 millones de clientes

Medicina de precisión y avances de detección genómica

Segmento de medicina de precisión	Valor de mercado global (2024)	Crecimiento proyectado
Oncología prueba genómica	$ 24.7 mil millones	12.3% CAGR
Cribado genómico cardiovascular	$ 8.3 mil millones	9.7% CAGR

Metodologías de diagnóstico alternativas

Tasas de adopción de tecnología de diagnóstico comparativo:

• Prueba de biopsia líquida: 37.2% de penetración del mercado
• Análisis de ADN tumoral circulante: adopción del 22.8%
• Detección genética impulsada por IA: implementación del 15,6%

Myriad Genetics, Inc. (Mygn) - Las cinco fuerzas de Porter: amenaza de nuevos participantes

Altas barreras reguladoras para la entrada del mercado de pruebas genéticas

El proceso de aprobación de la FDA para las pruebas de diagnóstico genético requiere documentación sustancial y validación clínica. A partir de 2023, el cronograma promedio de aprobación de la FDA para las tecnologías de pruebas genéticas es de 18-24 meses.

Requisito regulatorio	Costo de cumplimiento	Línea de tiempo promedio
FDA 510 (k) Liquidación	$250,000 - $500,000	12-18 meses
Estudios de validación clínica	$ 750,000 - $ 1.5 millones	18-24 meses

Requerido una inversión inicial sustancial

Los costos de investigación y desarrollo para las plataformas de diagnóstico genético son significativos.

• Inversión promedio de I + D para el inicio de las pruebas genéticas: $ 5-10 millones
• Costo de configuración de laboratorio inicial: $ 2-3 millones
• Equipo de secuenciación avanzada: $ 500,000 - $ 1 millón por unidad

Paisaje de propiedad intelectual

Categoría de patente	Costo promedio	Duración de protección
Patente de pruebas genéticas	$250,000 - $750,000	20 años
Patente de diagnóstico molecular	$350,000 - $850,000	20 años

Requisitos de experiencia científica especializada

El mercado de pruebas genéticas exige una fuerza laboral altamente especializada.

• Genetista promedio de doctorado Salario anual: $ 185,000
• Compensación anual especialista en bioinformática: $ 140,000 - $ 220,000
• Genetic Counseler promedio de salario anual: $ 85,000 - $ 120,000

Myriad Genetics, Inc. (MYGN) - Porter's Five Forces: Competitive rivalry

You're looking at a market where scale dictates staying power, and frankly, Myriad Genetics, Inc. is operating at a different weight class than its primary rivals. The competitive rivalry here is definitely fierce because the market for genetic testing-especially in hereditary cancer and prenatal diagnostics-is crowded with well-capitalized players. We see this immediately when you map out the revenue scale for fiscal year 2025 projections.

Myriad Genetics, Inc.'s reaffirmed 2025 revenue guidance sits in the range of $818M-$828M. To put that in perspective against the competition, you have to look at the multi-billion dollar entities that are aggressively pursuing the same patient populations and payer contracts. This revenue scale difference means Myriad Genetics, Inc. has less cushion for R&D investment or aggressive pricing actions compared to its larger peers.

Company	Latest Reported/Guidance Metric (2025)	Value
Myriad Genetics, Inc. (MYGN)	Full-Year Revenue Guidance	$818M-$828M
Natera, Inc. (NTRA)	Full-Year Revenue Guidance	$2.18 Billion-$2.26 Billion
Labcorp (LH)	Enterprise Revenue Guidance	$13.98 Billion-$14.13 Billion
Invitae (NVTA)	Reported 2025 Revenue	$592.94 Million USD

The rivalry intensifies because competitors often leverage their scale to undercut on price or offer more comprehensive testing menus. It's a volume game, and when you're competing against companies like Labcorp, which posted Q3 2025 revenue of $3.56 billion, the pressure on Myriad Genetics, Inc.'s average selling prices (ASPs) is constant. You see this dynamic play out in the push for broader accessibility.

Rivals are actively competing on the breadth of their offerings, which directly impacts market share in key areas. Here's where the competitive battle lines are drawn:

• Broader gene panels offered by competitors.
• Aggressive pricing strategies on multi-gene tests.
• Faster turnaround times for critical results.
• Increased payer coverage negotiations leverage.

The intensity is particularly sharp across the hereditary cancer and prenatal testing segments. For instance, Natera, Inc. is reporting record growth in its Signatera molecular residual disease (MRD) units, processing over 202,000 clinical MRD tests in Q3 2025. That's a direct challenge to Myriad Genetics, Inc.'s oncology franchise. Also, Natera raised its gross margin guidance to 62% to 64% for 2025, showing operational leverage that smaller players struggle to match while fighting price wars. If onboarding takes 14+ days, churn risk rises, especially when a competitor is touting superior speed.

Myriad Genetics, Inc. (MYGN) - Porter's Five Forces: Threat of substitutes

You're looking at the landscape for Myriad Genetics, Inc. (MYGN) and wondering how easily a patient or physician could choose something else instead of one of their established tests. The threat of substitutes is definitely real, especially as the diagnostic field evolves rapidly.

Alternative diagnostic methods, like traditional pathology or imaging, still exist, though they often lack the specific genetic insights Myriad Genetics, Inc. provides. For context, Myriad Genetics, Inc.'s total revenue for the third quarter of 2025 was $205.7 million, and their full-year 2025 revenue guidance is between $818 million and $828 million. This shows that while molecular diagnostics are significant, a large portion of the overall diagnostic market still relies on non-genetic methods.

The rapid adoption of liquid biopsy and AI-driven diagnostics presents a material threat because these technologies offer less invasive alternatives with potentially faster turnaround times for certain applications. The United States liquid biopsy market was valued at $1.21 billion in 2024 and is expected to grow at a robust Compound Annual Growth Rate (CAGR) of 14.99% from 2025 to 2033, or alternatively, is anticipated to surge from $4.03 billion in 2025 to reach $7.05 billion by 2030 with an 11.8% CAGR. Myriad Genetics, Inc. is actively responding to this by entering a strategic collaboration with SOPHiA GENETICS in September 2025 to develop a global liquid biopsy companion diagnostic (CDx) test. Furthermore, Myriad Genetics, Inc. intends to commercially launch its first AI-enabled prostate cancer test, in partnership with PATHOMIQ, in the first half of 2026, indicating a defensive move into this area.

Competitor's multi-gene panels can substitute Myriad Genetics, Inc.'s proprietary tests, often driven by payer decisions. The clearest example of this substitution pressure is the impact on the GeneSight test. UnitedHealthcare's discontinuation of coverage for multi-gene panel pharmacogenetic testing, including GeneSight, was effective in the first quarter of 2025. This headwind caused Pharmacogenomics revenue to fall by 20% in the first quarter of 2025, even as GeneSight test volume in the third quarter of 2025 grew 8% year-over-year, showing the underlying volume resilience when coverage is present. Still, the payer action is a direct substitution mechanism.

In-house lab developed tests (LDTs) by large hospital systems are another substitute, representing decentralized testing options that bypass centralized commercial labs. While specific revenue data for LDTs directly competing with Myriad Genetics, Inc. is not publicly detailed, the market trend shows movement in this direction. For instance, Exact Sciences launched Cancerguard, a multi-cancer early detection test, as a laboratory-developed test (LDT) in the U.S., partnering with Quest Diagnostics for blood collection access. This shows major players are using the LDT route to offer comprehensive testing outside of Myriad Genetics, Inc.'s traditional channels.

Here's a quick look at how the substitute market (Liquid Biopsy) is positioned against Myriad Genetics, Inc.'s recent performance:

Metric	Liquid Biopsy Market Data (Substitute)	Myriad Genetics, Inc. Q3 2025 Data
Market Size/Revenue	Projected to be $4.03 billion in 2025 (Source: ResearchAndMarkets.com)	Reported Revenue: $205.7 million
Growth Rate (CAGR)	11.8% (2025-2030) or 14.99% (2025-2033)	Hereditary Cancer Testing Volume Growth: 11% year-over-year
Key Competitive Action	Collaboration with SOPHiA GENETICS announced in September 2025	Gross Margin: 69.9%

You should watch for how Myriad Genetics, Inc. integrates its new liquid biopsy CDx development with SOPHiA GENETICS, and how quickly competitors roll out their own AI-driven tools, especially since Myriad Genetics, Inc.'s own AI test is slated for a first-half 2026 launch.

• UnitedHealthcare discontinued GeneSight coverage in Q1 2025.
• GeneSight revenue was $38.7 million in Q3 2025.
• Myriad Genetics, Inc. reported Q3 2025 Adjusted EBITDA of $10.3 million.
• Myriad Genetics, Inc. is launching an expanded gene panel for MyRisk test later in 2025.

Finance: draft 13-week cash view by Friday.

Myriad Genetics, Inc. (MYGN) - Porter's Five Forces: Threat of new entrants

The threat of new entrants into the molecular diagnostics space where Myriad Genetics, Inc. (MYGN) operates is moderated by significant upfront requirements, though the market's growth potential draws attention.

High regulatory hurdles and the need for clinical validation create barriers. To maintain its position, Myriad Genetics, Inc. shows a commitment to this by incurring research and development expense of $113.4 million for the year ended December 31, 2024, up from $88.7 million in 2023. This spending underpins the scientific research and collaborations necessary for regulatory alignment and advancing product utility, such as the ongoing work on its Precise MRD test with institutions like MD Anderson Cancer Center. New entrants face the same time and capital demands to achieve the necessary clinical validation and regulatory clearances, such as FDA authorization, which is a definite cost sink.

Securing national payer reimbursement contracts is a defintely high hurdle. The difficulty is evident in the real-world impact on existing players; Myriad Genetics, Inc.'s Pharmacogenomics revenue fell 20% year-over-year in the first quarter of 2025 specifically due to UnitedHealthcare reducing coverage for its GeneSight test. Furthermore, the precision medicine ecosystem is complex, involving Laboratory Benefit Managers (LBMs) and varied payer policies. Billing and coding complexities, with many tests using broad CPT codes instead of unique identifiers, lead to inconsistent payments and administrative burden for any new entrant trying to establish a national payer footprint.

The molecular diagnostics market's projected growth attracts new capital, despite the barriers. While the outline mentions a 9.1% CAGR, recent analyses show the broader global molecular diagnostics market is projected to grow from $45.11 billion in 2025 to around $63.86 billion by 2034, representing a CAGR of 3.87%. Other projections show a CAGR of 8.20% from 2025-2034, reaching $45.24 Billion. The US market alone is projected to be valued at $8.7 billion in 2025. This substantial, albeit variably projected, growth signals significant potential returns for well-capitalized entrants willing to navigate the regulatory and reimbursement maze.

Large, established diagnostic labs (e.g., Quest) can expand into genetic testing easily. These incumbents possess existing infrastructure, scale, and established payer relationships that new, pure-play genetic testing companies lack. For instance, Quest Diagnostics raised its full-year 2025 revenue forecast to a range of $10.80 billion to $10.92 billion, with its quarterly sales rising 15.2% to $2.76 billion in the second quarter of 2025. This scale allows them to absorb the costs of expanding their offerings, as seen by LabCorp and Quest Diagnostics expanding into Direct-to-Consumer (DTC) offerings through acquisitions. The established players are already integrated into the healthcare system, which is a major advantage when competing against specialized firms like Myriad Genetics, Inc.

Here's a quick look at the scale of established competitors versus Myriad Genetics, Inc. as of mid-2025:

Metric	Quest Diagnostics (Established Competitor)	Myriad Genetics, Inc. (MYGN)
Projected Full-Year 2025 Revenue (Range)	$10.80 Billion to $10.92 Billion	$807 Million to $823 Million
Q3 2025 Revenue	Not explicitly stated, but quarterly sales were $2.76 Billion in Q2 2025	$205.7 Million
Q3 2025 Gross Margin	Not explicitly stated	69.9%
Market Segment Dominance Indicator	Expanding into DTC via acquisition	Hereditary cancer testing volume grew 11% year-over-year in Q3 2025

What this estimate hides is the specific cost for a new entrant to build out a comparable national laboratory infrastructure and secure contracts with major payers like UnitedHealthcare, which can easily exert pricing pressure, as evidenced by the 20% revenue drop Myriad Genetics, Inc. experienced in one segment.

The barriers to entry for Myriad Genetics, Inc.'s competitors can be summarized by the required operational components:

• Achieving high laboratory efficiencies to maintain gross margins near 70%.
• Navigating payer disputes over reimbursement rates.
• Securing positive clinical validation in peer-reviewed journals.
• Maintaining positive adjusted EBITDA, which was $10.3 million for Myriad Genetics, Inc. in Q3 2025.
• Managing the impact of coverage decisions from major national payers.

Finance: draft 13-week cash view by Friday.